“ Troglitazone , a PPARγ agonist, exhibits significant anti-tumor activity and can alter glutamine metabolism in multiple cell types.”
“We found that troglitazone treatment suppressed glutamine uptake and the expression of the glutamine transporter, ASCT2, and glutaminase.”